Recent Research into the Rheumatoid Arthritis - Pipeline Review, H1 2016

Rheumatoid Arthritis - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

To access full report with TOC, please visit Rheumatoid Arthritis - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
- The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

3SBio Inc. 4D Pharma Plc 4SC AG AB Science SA AB2 Bio Ltd. AbbVie Inc. Ablynx NV ACEA Biosciences, Inc. Addex Therapeutics Ltd Advinus Therapeutics Ltd AlphaMab Co., Ltd Alteogen Inc. Amgen Inc. Amura Holdings Limited Anacor Pharmaceuticals, Inc. Applied Genetic Technologies Corporation ARA Healthcare Pvt. Ltd. Arena Pharmaceuticals, Inc. Arrien Pharmaceuticals, LLC Arthrogen BV Asahi Kasei Pharma Corp. Asana BioSciences, LLC Astellas Pharma Inc. AstraZeneca Plc Avexxin AS Axxam SpA BCN Peptides, S.A. Bio-Cancer Treatment International Limited BIOCAD Biocon Limited Biokine Therapeutics Ltd. BioLingus AG BioLite, Inc. Bionovis SA BioTherapeutics Inc. Bird Rock Bio, Inc. Boehringer Ingelheim GmbH Bone Medical Limited Boryung Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company Can-Fite BioPharma Ltd. Cardax Pharmaceuticals, Inc. etc,.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###